Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Methylation study of rapamycin treatment during development in mice

ABSTRACT: Methylation study of rapamycin treatment during development in mice

PROVIDER: PRJNA865244 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Methylation study of rapamycin treatment during development in mice

Project description:An Infinium microarray platform (HorvathMammalMethylChip320) was used to generate DNA methylation data from n=48 liver samples from mice. Treatment: encapsulated rapamycin treated or control mice

2022-08-05 | GSE210308 | GEO

Dynamic mRNA gene expression following a rapamycin treatment

2015-04-07 | GSE54851 | GEO

Rapamycin treatment of CEM_C1 cells 24 hours

Project description:Drug resistance remains a major obstacle to successful cancer treatment. Here we use a novel approach to identify rapamycin as a glucocorticoid resistance reversal agent. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in Acute Lymphoblastic Leukemia (ALL) cells. The screen indicated the mTOR inhibitor rapamycin profile matched the signature of GC-sensitivity. We thus tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells, and found that it sensitized cells to glucocorticoid induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis, and that the combination of rapamycin and glucocorticoids has potential utility in ALL. Furthermore this approach represents a novel strategy for identification of promising combination therapies for cancer. Keywords: drug treatment

2006-09-14 | GSE5821 | GEO

ChIP-on-Chip data from Rh30 cells +/- rapamycin treatment

Project description:p73 is a p53 family transcription factor that plays critical roles during development and tumor suppression. We analyzed p73 activity using a combination of ChIP-on-Chip and gene expression profiling, both at baseline and after treatment with the mTOR inhibitor rapamycin. We report the first comprehensive analysis of p73 binding across the genome. Furthermore, we re-analyzed this p73 cistrome after perturbation with rapamycin, an inhibitor of mTOR and inducer of p73. Multiple determinants of p73 binding, activity, and function were evident, and were modulated by mTOR.

2011-01-05 | GSE15704 | GEO

Full geroprotection from brief rapamycin treatment by persistently increased intestinal autophagy

Project description:The licensed drug rapamycin has potential to be repurposed for geroprotection. A key challenge is to avoid the adverse side-effects of clinical dosing regimes. Here we show a profound memory effect of brief rapamycin treatment. Brief, early adult treatment extended lifespan in Drosophila to the same degree as lifelong dosing. Lasting memory of earlier rapamycin treatment was mediated by elevated autophagy in enterocytes of the gut, accompanied by increased intestinal spermidine levels and improved structure and function of the ageing intestine. Brief elevation of autophagy itself induced a long-term increase in autophagy. In mice, short-term, 3-month treatment also induced a full memory effect, with enhanced autophagy in Paneth cells, improved Paneth cell architecture and gut barrier function at levels induced by chronic treatment, even 6 months after rapamycin was withdrawn. Past rapamycin treatment also enhanced the regenerative potential of aged intestine in intestinal organoids. Full geroprotective effects of chronic rapamycin treatment can thus be obtained with a brief pulse of the drug.

2022-07-18 | PXD020820 | Pride

Dynamic mRNA gene expression following a rapamycin treatment

Project description:Dynamic mRNA gene expression from the wildtype YSBN6 during a rapamycin treatment (rapamycin-induced downshift). Rapamycin was added to yeast cells growing exponentially on glutamine as sole nitrogen source. A sample was taken at steady-state 10 minutes before , and then 3, 7, 10, 14, 24, 56 and 120 minutes after rapamycin treatment. Biological triplicate gene expression was measured for samples -10, 7 and 24 minutes after shift, for a total of 14 chips. Changes were generally evaluated relative to the steady-state point (-10 minutes). Biological variability can be assessed from the replicates time points. Other dynamic omics data are associated with this dataset. Consult the publication for more details.

2015-04-07 | E-GEOD-54851 | biostudies-arrayexpress

Rhodosporidium toruloides haplotypes IFO0559 and IFO0880 rapamycin treatment

Project description:Comparison between control groups and rapamycin treatment of both haplotypes of Rhodosporidium toruloides.

2025-05-07 | PXD052386 | Pride

Examining changes in the chromosomal interaction network in replicative senescent, rapamycin treatment, and p65 inhibition

Project description:Analysis of HiC genome wide chromosomal interaction data in the context of replicative senescence, rapamycin treatment, the withdrawal of rapamycin, and with p65 inhibition in rapamycin withdrawal. This was done in order to determine what changes in chromosomal architecture occur during replicative senescence, and what impact rapamycin treatment or withdrawal or p65 inhibition has upon these changes.

2025-05-30 | GSE146584 | GEO

p73 activity and rapamycin treatment: ChIP-on-Chip and gene expression profiling studies

2011-01-05 | GSE15719 | GEO

RNA sequencing of liver and kidney tissues from mice treated with rapamycin during development

Project description:RNA sequencing of mouse liver and kidney. UMHET pups were treated with diet containing encapsulated rapamycin or encapsulating material as a control from birth to 45 days of age, and tissues were collected at 2, 20-22 and 27-29 months of age from both males and females, and 3-5 samples per age, sex and treatment were sequenced.

2022-07-13 | GSE207865 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data